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a  b  s  t  r  a  c  t
Vaccination  has  been  one  of  the most  successful  public  health  measures  since  the introduction  of basic
sanitation.  Substantial  mortality  and  morbidity  reductions  have  been  achieved  via vaccination  against
many  infections,  and  the  list  of  diseases  that  are  potentially  controllable  by  vaccines  is growing  steadily.
We  introduce  key  challenges  for  modeling  in shaping  our understanding  and  guiding  policy  decisions
related  to vaccine  preventable  diseases.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Mathematical modeling has made key contributions to vac-
cination program design, from introducing the concept of herd
immunity thresholds to predicting changes in post-vaccination epi-
demiology (such as increasing age at infection (Knox, 1980) and
increasing inter-epidemic intervals). Nonlinearities in transmis-
sion dynamics mean that intuition may  miss important aspects of
the impact of vaccination programs that mechanistic models can
reveal. Models also allow investigation of the potential impact of
uncertainties in our understanding of contact processes, vaccine
protection and future uptake. Consequently, models are becoming
embedded in the decision-making process for global vaccine use.
Many key insights have been derived from simple models, par-
ticularly for those disease and vaccines that generate life-long
sterilizing immunity (e.g., measles). However, these infections
represent one end of a long spectrum. Most disease systems
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are much more complex, with vaccines being imperfectly effec-
tive in a variety of ways (Halloran et al., 2010). The same basic
sets of questions pertain to these infections (e.g., quantifying
spatial and social heterogeneity in susceptibility); and correspond-
ing modeling challenges arise. Further, the development of new
vaccines for infections with more complex dynamics and less com-
plete immune action, combined with increasingly detailed policy
questions regarding the implementation and effectiveness of vac-
cination programs, raises a number of new challenges in deploying
dynamic models to support program design and evaluation. Here,
we ﬁrst outline challenges emerging at the population level (vac-
cine distribution and logistics, Challenges 1–3) and then detail some
of the challenges that emerge in better describing the underlying
biology of vaccination (Challenges 4–7).
1. Quantifying spatial and social heterogeneity in natural
and vaccine-induced immunity
Immunological heterogeneity within a population is a major
public health challenge, leaving pockets of people ‘silently’ unpro-
tected, and hampering elimination efforts. Heterogeneity may
result from differential uptake of vaccination, or from differences
http://dx.doi.org/10.1016/j.epidem.2014.08.004
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in prior history of infection, or in underlying immunocompetence.
Under-immunized groups may  be vulnerable to outbreaks, even
if they are part of a population in which, on average, vaccina-
tion coverage is high. The most commonly used coverage estimate,
the number of doses delivered divided by target population size
(Burton et al., 2009), can mask worrying levels of local heterogene-
ity.
Heterogeneity leading to low uptake can be a result of poor
access to healthcare, recent migration and/or displaced popula-
tions, as well as cultural or religious attitudes about vaccination.
Developing models that use existing data sources to quantify spatial
and social heterogeneity in vaccine coverage, and hence immu-
nity, is a major challenge. It is important to understand both the
size (Lessler et al., 2011) and the identity of poorly served groups,
and to understand why and where pockets of unvaccinated individ-
uals arise dynamically. Models that can predict changes in vaccine
demand over time, especially those linked to the spread of either
complacency toward the need for vaccination, or suspicions of
vaccine side-effects (Funk et al., 2010) will have immediate appli-
cations for public health policy (e.g. measles in Europe).
A related challenge is developing models that quantify the
importance and dynamical consequences of social vs. spatial het-
erogeneity. For example, if vaccine refusers (i.e., individuals who
actively reject vaccination when offered, with motivations ranging
from complacency to conviction of the harmful effects of vaccina-
tion for their children; see also Funk et al., 2014) are clustered in
space, the consequences for transmission and control are different
than if they are spatially dispersed but socially connected. There is
a further distinction between socially connected people who  regu-
larly meet (e.g., in schools) and those who do not (e.g. are connected
through social media, etc. (Eames, 2009)). These distinctions will
affect the best strategy for increasing vaccine uptake (e.g., local
campaigns within communities vs. social-network driven cam-
paigns). There is also a need to understand under what conditions
such clusters become at risk for epidemic spread, and the risk they
pose to surrounding groups where vaccine coverage may  be high.
As the degree of social and spatial heterogeneities increases, dif-
ferential equation model-based approaches become increasingly
unwieldy, and alternative methods may  be a fruitful direction for
research. While there has been much development recently in
models that explicitly take population heterogeneities into account
(Danon et al., 2011), it remains unclear how these relate to issues of
vaccine coverage and resulting outbreak patterns. A related set of
challenges concerns development of methods that can leverage the
vast quantities of digital data relating to social media, and engage
with all the associated limitations of these types of data (Salathé
and Khandelwal, 2011).
Increasingly, serology is recognized as an important element of
the public health evaluation of outbreaks and vaccination coverage
(Wu,  2011; Van Kerkhove, 2010). Availability of serological data
sources may  enable improved mapping of susceptibility, but since
an individual may  be seropositive either as a result of having been
vaccinated, or from having been infected (so seropositivity could
be a marker of success or failure of a vaccination program) models
will be needed to interpret these surveys. Serological markers also
vary in their interpretability across diseases. Enhanced modeling
of such data would improve both ‘nowcasting’ and ‘forecasting’ of
immunity in the population. Dynamical models could also explore
how to optimize reactive vaccination strategies triggered by such
serological information.
2. Logistics and economics of vaccine delivery
High penetration of vaccination throughout a country is a major
public health challenge, and is essential to an effective vaccination
program, particularly if elimination is the goal (see also Klepac et al.,
in preparation). Models of targeted program delivery, the delivery
system itself, the economics of, and behavioral responses to vacci-
nation (Funk et al., 2014; Brito et al., 1991) have the potential to
identify bottle necks and solutions. When resources are limited, a
vaccination program must not only be effective, but also carried out
economically.
Emergency situations are one key context where models can
support vaccination delivery programs. For example, effective
deployment of vaccines in emergency contexts characterized by
limited vaccine supply (e.g., cholera) may  rest on the relative merits
of reactive vaccination vs. mass vaccination of “hotspots”. Mod-
els may  contribute to distinguishing between these two  strategies.
Since data in fast moving outbreak situations may be available
with a lag of several days while the logistics of vaccination deploy-
ment may  require weeks; models must both rise to the challenge of
rapidly responding to the (often partial) data available, and taking
into account explicit time-scales of delivery. Even where vaccine
supplies are not limiting (i.e., measles, or meningococcal disease
rather than cholera), the relative time-scales of delivery and spread
of an outbreak through an under-vaccinated group (for measles,
see Challenge 1) may  mean that the outbreak is likely to extin-
guish itself before the intervention can take effect. Alternatively,
the cost of running the intervention may  not be justiﬁed given its
likely impact. Finally, there is the question of when vaccination
efforts can be halted in an outbreak situation (which hinges on the
dynamic consequences of vaccination). Models may contribute to
evaluating all of these outcomes.
The success of many of the models rests on the availability and
quality of data used for parametrization – which in turn, often rests
on obtaining the conﬁdence and support of vaccine program man-
agers, or other policy makers. To ensure that decisions are made
on the best available data, recommendations need to be communi-
cated and acted upon promptly; furthermore, to retain conﬁdence
in the usefulness of the modeling approach in the face of chang-
ing outcomes, a key challenge is that of communicating model
methodologies and conclusions effectively (see Metcalf et al., in
preparation). Even with the full support of key players, data (on
both incidence and vaccination coverage) is often incomplete and
fraught with uncertainty. The development of models that can
address these issues is a very general challenge that emerges across
all of the major challenges mentioned here.
A related set of questions that modeling could inform is the
design of supply chains and the infrastructure of delivery and deci-
sion making (Lee et al., 2012). Models are currently used to inform
decisions made on cost-effectiveness grounds. Models should also
be used to evaluate such decisions: how reliable have estimates
been? How good are the data – on delivery costs and coverage – that
have gone into modeling; can uncertainty be reduced to make mod-
els more straightforward to interpret? How can existing programs
best collaborate to optimize outcome – e.g. by delivering multiple
vaccines at a single visit or enhancing the healthcare infrastructure?
These issues are especially pertinent in the context of complexi-
ties of transboundary issues and complex funding of international
vaccination efforts (Klepac et al., 2011).
3. Quantifying the dynamics at vaccination levels near the
critical vaccination threshold
Early modeling work on vaccine-preventable infections was
based in contexts where infection was endemic and in which every
individual was  likely to be exposed to infection. This research gen-
erated a detailed understanding of the dynamic interplay between
susceptible recruitment, infection and immunity (e.g., Fine and
Clarkson, 1986; Grenfell et al., 2001; Bolker and Grenfell, 1995).
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However, as vaccine coverage reaches higher levels, for an increas-
ing number of infections, key assumptions underlying these models
no longer hold.
As vaccination levels approach the critical vaccination thresh-
old (the point at which the effective reproduction number, RE, falls
below one), large parts of the population will not have encoun-
tered the infection, and patterns of immunity will be almost entirely
determined by past and present vaccination uptake. As dynamic
patterns change from endemicity to outbreaks of varying size
(Jansen et al., 2003), infection shifts into (i) older age groups and
(ii) susceptible pockets in hard-to-reach populations (those with
poor access to health care, displaced populations, migrants, areas
where vaccinators may  be at risk), and populations who  chose to be
hard to reach (refusers; see Challenge 2). This opens the challenge
of developing models that take into account changes in contact pat-
terns of those infected. It has been shown that children have more
contacts than adults do (Mossong et al., 2008). As the burden of
infection moves into older age groups, does this mean that herd
immunity is easier to achieve? Since infection will be focused in
particular clusters of susceptibles, should we reconsider the scale at
which we must measure vaccination coverage: from a country to a
city, borough, or social group? The relevant patterns of contact may
change from mixing between age groups to interactions between
speciﬁc social groups in different locations. If susceptible clusters
are connected on the scale of a country or continent, can infection
persist in these clusters even if overall levels of vaccination are
above the critical vaccination threshold? The appropriate model-
ing approach may  no longer be the familiar spatially homogeneous
mass-action model, but a spatially extended metapopulation with
each patch representing a particular under-vaccinated community
(Keeling et al., 2004). Answering these questions may  require care-
ful reconsideration of concepts such as that of Critical Community
Size (Bartlett, 1957).
As natural disease circulation ends, any immune boosting due to
natural exposure is likely to end. For many vaccines it is unclear if
vaccine induced immunity will be maintained for the same length
of time when disease does not circulate as when it does. If we  can
fully understand the immunodynamics (see Challenge 4), models
can play a critical role in predicting how population immunity will
change once disease circulation stops, and if changes in vaccina-
tion policy, for example additional booster doses at older age, may
be needed to prevent re-emergence or protect newly vulnerable
populations (e.g., the elderly). How to best address the resulting
problem of scale (e.g. linking within-host immune processes with
population effects such as herd immunity) remains an open and
important question.
4. Model immunodynamics – when are protective vaccines
possible, and how can we measure protection?
Vaccines can be imperfect in a variety of ways – they may
work in some people and not others (referred to as vaccine ‘take’),
they may  reduce susceptibility by some amount in all individuals
(‘degree’) and protection may  wane over time (‘duration’) (McLean
and Blower, 1995). The success of vaccines at an individual level
is determined by the detailed dynamics of the immune system
and the kinetics underlying maintenance of immune memory. Dur-
ing the last decade, experimental immunology has provided an
enormous richness of detail of the cell biology and proteomics
responsible for the cascade of events associated with clearance of
infection (e.g. Pilyugin and Antia, 2000; Thakar et al., 2009). A key
future challenge is to develop models that can address wildly dif-
ferent time scales associated with such clearance (cytokines are
up-down regulated in minutes or hours while immune memory is
lifelong or decays over decades) and capture redundancies within
the immune system (e.g. Bergstrom and Antia, 2006). Intermediate
models may  be part of the solution, clarifying the relative roles of
cell-mediated versus humoral responses, and explaining the emer-
gent simplicity of pathogen persistence or clearance in the face of
the bewildering underlying biological complexity.
The duration of protection is related to the population dynamics
and homeostatic regulation of memory B and T cells. Mathemati-
cal theory has contributed importantly to this area, clarifying the
kinetics of memory cell proliferation, their antigen-dependence
versus -independence of maintenance and the overall longevity
of memory (for a review see Antia et al., 2005). However, many
obvious questions remain, both at the scale of the ‘autecology’
of speciﬁc memory lineages, and the ‘community ecology’ of the
whole memory assemblage. Developing models of the subtleties of
these dynamics is important for the success of the next generation
of vaccines that propose to use, say, adeno- or herpes virus vectors
to produce T cell vaccines (Arinaminpathy et al., 2012a).
Carefully calibrated immunodynamic models will ultimately
touch on a large number of critical immune- and vaccine-related
questions such as: what are the causes of and the role of persis-
tent pathogen circulation in the maintenance of herd immunity
(e.g. Lavine et al., 2011)? Can we  distinguish fast waning and natu-
ral boosting, from slow waning and no boosting? Do such different
scenarios produce qualitatively different dynamics and/or serology
proﬁles? What are the immunodynamics responsible for protecting
against infection, against disease, and against onward transmis-
sion? Designing models of a scale appropriate to answer these
questions is a big theoretical challenge.
5. Investigate when vaccines are evolution proof and when
they are not
From an evolutionary perspective, the existence of pathogens
for which immunity (natural or vaccinal) is life-long are surpris-
ing, since selection pressures favoring escape mutants will be
vast (see Metcalf et al., 2014). Modeling infectious disease sys-
tems characterized by continuous immune escape from natural,
and vaccine derived, immunity (e.g., inﬂuenza, Marek’s disease
Atkins et al., 2013) may  provide insights into “evolution prooﬁng”
medical interventions. Some initial work points to interesting long-
term consequences of even partially effective vaccines against such
pathogens, including reduction of transmission rates, improve-
ment of herd immunity, and potentially slowing down of antigenic
drift (Arinaminpathy et al., 2012b). Conversely, in systems where
between-strain competition is important, models indicate that vac-
cines with broad targets may  not always be better than more
speciﬁc ones (Flasche, 2013). A large part of the challenge is iden-
tifying where modeling could supply insight – for example, two
pathways seem possible for inﬂuenza: T-cell immunity, or anti-
bodies to conserved regions on the stalk protein. How should this
be modeled? An interesting direction might be the development of
a framework similar to the pharmaco-kinetic/pharmaco-dynamic
model used for drugs; and then extending this to encompass selec-
tion pressures, and some of the detail of underlying mechanism.
Further extending this to assess the role of population level pro-
cesses such as age-structure (Lange and Ferguson, 2009) provides
additional challenges.
We currently have no tools to evaluate signatures that might
reﬂect vaccine escape, inform us about how soon we might expect
to see vaccine escape, what age groups might be affected, and how
vaccine escape might be distinguished from inefﬁcacious vaccines.
In the simplest analysis, vaccine escape might be thought of as a
gradual process, occurring at a rate proportional to the cumulative
number of cases, and therefore likely to make its effects known
later in any given outbreak. However, effects of stochasticity and
14 C.J.E. Metcalf et al. / Epidemics 10 (2015) 11–15
heterogeneity are likely to make such a distinction difﬁcult to
observe in practice, and models will be required to guide surveil-
lance.
6. Determine the implications of radically new vaccine
technologies
Recent technological advances have led to the development of
vaccines whose effects do not mimic  natural immunity, and where
modeling might make considerable contributions to anticipating
public health outcomes. These include vaccines against bacterial
pathogens involving multiple serotypes associated with complex
carriage and disease states, such as meningococcal and pneumo-
coccal vaccines (see Challenge 7), and broad-based viral vaccines;
universal inﬂuenza vaccines; multivalent dengue and human papil-
loma virus (HPV) vaccines. A proposed hepatitis C vaccine may
not necessarily prevent the initial infection, but may  prevent the
chronic stages of the disease that eventually leads to cirrhosis or
potentially death (Plotkin et al., 2013). This is uncharted territory,
as the population-level beneﬁts of such vaccines are unclear, and
the population dynamics and acquisition of immunity are typically
more complex than in other more traditional vaccine-preventable
disease systems.
The poster child for the issue of immune enhancement is
dengue. Primary infection with one serotype may  predispose for a
more severe infection with another serotype (hemorrhagic fever).
This has hampered the development of safe dengue vaccines for the
last few decades. How immune enhancement may  affect the long-
term prospects of tetravalent dengue vaccines currently in clinical
trials has only begun to be addressed by the modeling community
(Chao, 2012; Coudeville and Garnett, 2012; Rodriguez-Barraquer
et al., 2014). Key challenges remain, including modeling local het-
erogeneities in serotype distributions and their transmissibility,
mostly as a result of paucity of epidemiological and virological
data, especially in settings where the epidemiology of dengue is
rapidly changing such as South America. In addition, models have
to account for the complex and still debated biological mechanisms
responsible for immune enhancement, and the lower efﬁcacy of
existing vaccines to a subset of serotypes (Rodriguez-Barraquer
et al., 2014).
7. Account for the microbial community ecology of
vaccination
Increasingly, vaccines are being developed for systems where
the community context of focal pathogens is complex. Predicting
outcomes in these novel contexts is of clear public health impor-
tance and comes with its own set of modeling challenges.
There are two ways in which complex interactions can occur.
First, vaccines may  induce differential selection pressure on par-
ticular strains of the pathogen, thus indirectly affecting pathogen
evolution. Vaccine escape strains of pertussis and Marek’s disease
offer striking examples, but the introduction of multivalent vac-
cines (that protect against a targeted subset of the strains in a
pathogen complex) all have this potential, and can lead to vaccine-
induced strain replacement. While the pneumococcal vaccine now
includes up to 13 serotypes historically associated with severe
infections, it does not fully cover the population of circulating
serotypes (estimated at ∼100). While invasive pneumococcal dis-
ease rates have declined in countries using the vaccine, serotype
replacement has occurred in a number of developed countries,
with non-vaccine serotypes accounting for an ever larger pro-
portion of carriage and disease (Weinberger et al., 2011). It is
challenging to model the long-term beneﬁts of such programs with
little information on what makes a serotype pathogenic, especially
in developing country settings. Further modeling challenges are
to accurately represent the multi-strain dynamics of circulating
pathogens and duration of vaccine-induced immunity, while pre-
dicting the pathogenic potential of non-vaccine serotypes that may
emerge or become more predominant over time. The outcome of
pathogen evolution will depend on the exact nature of the inter-
action between the strains, and may  in fact also depend on host
population structure. We  need models that can tell us how strain
replacement depends on the nature of the strain interactions. Host
population structure may  also affect the potential for strain replace-
ment, since the removal of a superior competitor may release less
ﬁt strains into the vacated niche.
Second, vaccines against one organism may  have indirect effects
on others. For example, bacterial pneumonia is a known cause of
mortality following inﬂuenza infections, but we  have not yet under-
stood how this will be affected by new inﬂuenza and bacterial
vaccinations. Further, the morbidity associated with commensal
pathogens, and in particular meningitis, which only cause disease
under speciﬁc circumstances is not well understood within the con-
text of disease transmission dynamics. Human challenge studies
show that bacteria that share a niche are characterized by colonies
of different strains and species expanding and contracting dynam-
ically. We  do not yet know the impact of vaccinating against one
species on the dynamics of the others. Modeling will play an essen-
tial role in interpreting new experimental and surveillance studies
of these issues.
Conclusions
The overwhelming public health success of vaccines to date is
largely attributable to vaccines that provide long-lived immunity.
With a few exceptions (e.g., rubella), what modeling had to offer in
these cases was  mostly a matter of reﬁnement, as distributing more
vaccine always led to less disease. The situation is more complex in
the modern vaccine era. The focus for tried and true vaccines has
shifted from individual protection, to elimination and maintaining
immunity (and enthusiasm for vaccination) in the absence of dis-
ease circulation. New vaccine products lead us to confront more
complex disease systems (dengue, HPV) where vaccination may
carry its own risks or cause ecological disruptions with unknown
consequences. In this new era, we  need more sophisticated model-
ing methodologies that capture the complexities of these systems
and can account for geographic and social heterogeneity in risk and
vaccine use. There is also the opportunity for mechanistic mod-
els to play new roles beyond predicting vaccine effectiveness. The
models of the future may  be used to confront logistical constraints,
help translate data into measurements of program (or vaccine) per-
formance, and even guide the biological development of vaccine
products.
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